WO2009151016A1 - 1-ビフェニルメチルイミダゾール化合物の製造方法 - Google Patents
1-ビフェニルメチルイミダゾール化合物の製造方法 Download PDFInfo
- Publication number
- WO2009151016A1 WO2009151016A1 PCT/JP2009/060419 JP2009060419W WO2009151016A1 WO 2009151016 A1 WO2009151016 A1 WO 2009151016A1 JP 2009060419 W JP2009060419 W JP 2009060419W WO 2009151016 A1 WO2009151016 A1 WO 2009151016A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- production method
- formula
- group
- reaction
- Prior art date
Links
- VRLDVERQJMEPIF-UHFFFAOYSA-N CC(C)(C(N(C1=O)Br)=O)N1Br Chemical compound CC(C)(C(N(C1=O)Br)=O)N1Br VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N CCCc1nc(C(C)(C)O)c(C(O)=O)[n]1Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1 Chemical compound CCCc1nc(C(C)(C)O)c(C(O)=O)[n]1Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- PZPSZIYVSFBMGX-UHFFFAOYSA-N CCCc1nc(C(C)(C)O)c(C(OCC)=O)[n]1Cc(cc1)ccc1-c(cccc1)c1C#N Chemical compound CCCc1nc(C(C)(C)O)c(C(OCC)=O)[n]1Cc(cc1)ccc1-c(cccc1)c1C#N PZPSZIYVSFBMGX-UHFFFAOYSA-N 0.000 description 1
- NQKKUSLBNWTXQI-UHFFFAOYSA-N CCOC(c1c(C(OCC)=O)nc[nH]1)=O Chemical compound CCOC(c1c(C(OCC)=O)nc[nH]1)=O NQKKUSLBNWTXQI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to a novel method for producing a 1-biphenylmethylimidazole compound [preferably, the following compound (13a)] having an excellent angiotensin II receptor antagonistic activity or an intermediate thereof.
- Method X is known as a method for producing an imidazole compound using tartaric acid diester (see Patent Document 2).
- Y method is known as a method for producing 1- (tetrazolylbiphenylmethyl) imidazole compound from 1- (cyanobiphenylmethyl) imidazole compound (see Patent Document 3).
- Method Z is known as a method for producing 1-biphenylmethyl-4- (1-hydroxy-1-methylethyl) imidazole compound from 1-biphenylmethyl-4-methoxycarbonylimidazole compound (see Patent Document 4). .
- the reaction proceeds efficiently in an industrial reaction vessel such as a reaction vessel, the total yield is high, the selectivity of the reaction is high, the target compound is provided with high purity, and the number of reaction steps is small.
- An excellent production method is desirable in that the reaction is safe.
- the inventors of the present invention have made extensive studies on a method for producing a 1-biphenylmethylimidazole compound [preferably the following compound (13a)] or an intermediate thereof, and the novel production method of the present invention is known from an industrial viewpoint. It was found to be superior to the manufacturing method. The present invention has been completed based on the above findings.
- the present invention provides a novel method for producing a 1-biphenylmethylimidazole compound [preferably, the following compound (13a)] having an excellent angiotensin II receptor antagonistic activity or an intermediate thereof.
- the production method of the present invention is shown in the following Method A [Method A (1) and Method A (2)] or Method B.
- R 1 represents a C 1 -C 4 alkyl group
- R a represents a C 1 -C 4 alkyl group
- R b represents a C 1 -C 6 alkyl group
- X represents chloro Group represents a bromo group or an iodo group
- Tr represents a triphenylmethyl group.
- the present invention provides the following [1] to [33]. [1] Formula (1)
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- a compound having the formula R 1 C (OR b ) 3 [wherein R 1 represents a hydrogen atom or a C 1 -C 4 alkyl group, and R b represents a C 1 -C 6 alkyl group.
- R 1 represents a hydrogen atom or a C 1 -C 4 alkyl group
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- R 1 is a 1-propyl group
- R a is an ethyl group
- the radical initiator is 2,2′-azobis (4-methoxy-2,4-dimethylvaleronitrile)
- the oxidizing agent is 1,3-dibromo-5,5-dimethylhydantoin
- the ammonia generating reagent is ammonium acetate
- a compound having the formula R 1 CHO is used, and the reaction is carried out under shading conditions, [1 The manufacturing method described in].
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- the manufacturing method of the compound which has this. [14] The production method according to [13], wherein R a is an ethyl group, the radical initiator is an azobis compound, and the oxidizing agent is a halogenosuccinimide compound or a dihalogenohydantoin compound.
- R a is an ethyl group
- the radical initiator is 2,2′-azobis (4-methoxy-2,4-dimethylvaleronitrile)
- the oxidizing agent is 1,3-dibromo-5
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- a compound having Formula M (N 3 ) n [wherein M represents an alkali metal or an alkaline earth metal, and n represents 1 or 2.
- the manufacturing method of the compound which has this [17] The production method according to [16], wherein R a is an ethyl group. [18] The production method according to [16] or [17], wherein the inorganic azide salt is sodium azide. [19] The cyclic amine salt is N-methylpyrrolidine, N-methylpiperidine, N, N-dimethylpiperazine, N-methylmorpholine, N-methylthiomorpholine, N-methylhomopiperidine, or N, N-dimethylhomopiperazine. The production method according to any one of [16] to [18], which is a hydrochloride or hydrobromide salt.
- the cyclic amine salt is N-methylpiperidine, N, N-dimethylpiperazine, N-methylmorpholine, or a hydrochloride or hydrobromide of N-methylthiomorpholine.
- R a is an ethyl group
- the inorganic azide salt is sodium azide
- the cyclic amine salt is N-methylpyrrolidine, N-methylpiperidine, N, N-dimethylpiperazine, N-methylmorpholine. , N-methylthiomorpholine, N-methylhomopiperidine, or the hydrochloride or hydrobromide salt of N, N-dimethylhomopiperazine.
- R a is an ethyl group
- the inorganic azide salt is sodium azide
- the cyclic amine salt is N-methylpiperidine hydrochloride, N, N-dimethylpiperazine dihydrochloride, or N—
- R 1 represents a hydrogen atom or a C 1 -C 4 alkyl group
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- R 1 represents a hydrogen atom or a C 1 -C 4 alkyl group
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- the manufacturing method of the compound which has this. [25] The production method according to [24], wherein R 1 is a 1-propyl group, and R a is an ethyl group. [26] The production method according to [24] or [25], wherein X is a chloro group. [27] The production method according to [24], wherein R 1 is a 1-propyl group, R a is an ethyl group, and X is a chloro group.
- Formula (13a) including the production method according to any one of [1] to [12] as a part of the reaction step
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- R a represents a hydrogen atom or a C 1 -C 4 alkyl group.
- C 1 -C 4 alkyl in R 1 represents linear or branched alkyl having 1 to 4 carbon atoms, for example, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl. 2-butyl or 2-methyl-2-propyl, preferably 1-propyl or 1-butyl, most preferably 1-propyl.
- C 1 -C 4 alkyl in R a represents straight or branched alkyl having 1 to 4 carbon atoms, for example, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl 2-butyl or 2-methyl-2-propyl, preferably methyl or ethyl, and most preferably ethyl.
- R a is preferably a C 1 -C 4 alkyl group.
- C 1 -C 6 alkyl for R b represents straight or branched alkyl having 1 to 6 carbon atoms, for example, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl , 2-butyl, 2-methyl-2-propyl, 1-pentyl, or 1-hexyl, preferably methyl or ethyl, and most preferably methyl.
- the “alkali metal” in M is preferably lithium, sodium, or potassium, and most preferably sodium.
- the “alkaline earth metal” in M is preferably magnesium or calcium.
- X is preferably a chloro group or a bromo group, and most preferably a chloro group.
- the compound related to the present invention can form a hydrate or a solvate by placing in the air or mixing with water or an organic solvent. These hydrates or solvates are included in the compounds related to the present invention.
- the chemical purity of the compound or the content of the compound as an impurity can be determined in accordance with a method well known in the field of organic chemistry, for example, in high performance liquid chromatography (hereinafter also referred to as HPLC).
- HPLC high performance liquid chromatography
- the peak area ratio or weight% can be determined preferably by the peak area ratio in HPLC.
- HPLC measurement conditions can be selected as appropriate.
- the production method of the present invention can be carried out according to the following method A or method B.
- R 1 , R a , R b , M, X, and Tr are as defined above.
- the compound having the formula (1) is also referred to as a compound (1). The same applies to other numbered compounds.
- the solvent used in the reaction in each step of Method A or Method B is not limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent, and is selected from the following solvent group, for example.
- Solvent group includes aliphatic hydrocarbons such as hexane, pentane, petroleum ether, and cyclohexane; aromatic hydrocarbons such as benzene, toluene, and xylene; Isopar E (manufactured by Shell), Isopar G (manufactured by Shell) , Isopar H (made by Shell), Isopar L (made by Shell), Isopar M (made by Shell), IP Clean LX (made by Idemitsu), IP Clean HX (made by Idemitsu), IP Solvent 1620 (made by Idemitsu) ), IP Solvent 2028 (manufactured by Idemitsu), Marcazole R (manufactured by Maruzen), Marcazole 8 (manufactured by Mar
- reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is appropriately selected.
- reaction time varies depending on the solvent, starting materials, reagents, reaction temperature, etc., and is appropriately selected.
- the target compound in each step can be isolated from the reaction mixture according to a well-known method.
- the target compound is extracted, for example, by (i) removing insoluble matters such as a catalyst as necessary, and (ii) adding water and a solvent immiscible with water (for example, ethyl acetate) to the reaction mixture. And (iii) if necessary, the organic layer is washed with water and dried using a desiccant (such as anhydrous magnesium sulfate), and (iv) the solvent is distilled off.
- a desiccant such as anhydrous magnesium sulfate
- the target compound can also be obtained by (v) adding a solvent that does not dissolve the target compound (eg, water) to the reaction mixture, adjusting the pH of the reaction mixture as necessary, and collecting the precipitated crystals by filtration. can get.
- the obtained target compound can be further purified by a known method (for example, recrystallization, reprecipitation, silica gel column chromatography, etc.) as necessary.
- the obtained target compound can also be used in the next reaction without purification.
- Step A-1 is a step for producing compound (2) by oxidizing known compound (1) with an oxidizing agent in the presence of a radical initiator and an acid.
- an optical isomer or a racemate thereof can be used in place of the compound (1).
- the radical initiator used is not particularly limited as long as it can initiate a radical reaction.
- the relative amount of the radical initiator reagent relative to compound (1) is usually a catalytic amount, preferably 0.001 to 50 mol%, more preferably 0.005 to 10 mol%, Most preferably, it is 0.01 to 1 mol%.
- acids used include organic acids such as formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, trifluoroacetic acid, pentafluoropropionic acid; methanesulfonic acid, benzenesulfone Acids, organic sulfonic acids such as p-toluenesulfonic acid, camphorsulfonic acid, trifluoromethanesulfonic acid; or inorganics such as hydrogen chloride, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid, nitric acid It can be an acid, preferably an organic acid, and most preferably acetic acid.
- organic acids such as formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, trifluoroacetic acid, pentaflu
- halogenosuccinimide compounds such as N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide
- Dihalogenohydantoin compounds such as 1,3-dichloro-5,5-dimethylhydantoin and 1,3-dibromo-5,5-dimethylhydantoin [compound (16)]; bromine; sodium chlorite, chlorous acid Chlorite like potassium; Bromate like sodium bromite and potassium bromite; Hypochlorite like sodium hypochlorite and potassium hypochlorite; Hypobromite Sodium, hypobromite such as potassium hypobromite; manganese compound such as potassium permanganate, manganese dioxide; or A periodate compound such as sodium periodate, periodate, preferably a halogenosuccinimide
- the solvent used is preferably an aromatic hydrocarbon, an ether, an ester, or an organic acid, more preferably an ester or an organic acid, and even more preferably an organic acid. And most preferred is acetic acid.
- the reaction temperature is preferably 0 to 100 ° C, and more preferably 20 to 80 ° C.
- the reaction time is preferably 30 minutes to 12 hours, and more preferably 1 to 6 hours.
- Step A-1 and Step A-2 can be performed under light-shielding conditions or under non-light-shielding conditions, and preferably under light-shielding conditions.
- “Shading” includes “complete shading” indicating that the reaction solution is not exposed to light at all, and “substantial shading” indicating that the reaction solution is hardly exposed to light. It is a shading.
- step A-2 is carried out continuously without isolating compound (2) obtained in step A-1.
- Step A-2 is a step of producing compound (5) by reacting compound (2) with an ammonia-producing reagent and compound (3) or compound (4).
- ammonia generating reagent used is, for example, an ammonium salt such as ammonium acetate, ammonium propionate, ammonium isobutyrate, ammonium pivalate, ammonium carbonate; or aqueous ammonia, preferably an ammonium salt, most Ammonium acetate is preferred.
- an ammonium salt such as ammonium acetate, ammonium propionate, ammonium isobutyrate, ammonium pivalate, ammonium carbonate
- aqueous ammonia preferably an ammonium salt, most Ammonium acetate is preferred.
- the compound (3) used is preferably formaldehyde, acetaldehyde, propanal, 1-butanal or 1-pentanal, and most preferably 1-butanal.
- the compound (4) used is preferably a formic acid orthoester such as methyl orthoformate or ethyl orthoformate; an acetic acid orthoester such as methyl orthoacetate or ethyl orthoacetate; methyl orthopropionate or ethyl orthopropionate
- a propionic acid orthoester such as methyl orthobutanoate, a butanoic acid orthoester such as ethyl orthobutanoate; or a pentanoic acid orthoester such as methyl orthopentanoate, more preferably a butanoic acid orthoester.
- compound (3) is preferably used.
- the solvent used is preferably an ether, nitrile or alcohol, more preferably an ether, and still more preferably tetrahydrofuran, dioxane or 1,2-dimethoxyethane. Most preferred is tetrahydrofuran or 1,2-dimethoxyethane.
- the reaction temperature is preferably 0 to 100 ° C, and more preferably 20 to 80 ° C.
- the reaction time is preferably 30 minutes to 48 hours, and more preferably 1 to 6 hours.
- Compound (5) can also be obtained as a salt by combining with an acid.
- the acid that forms a salt with compound (5) is not particularly limited as long as it can form a salt with an amine, and can be, for example, the acid shown in Step A-5, preferably an organic acid or inorganic acid.
- An acid more preferably acetic acid, trifluoroacetic acid, hydrochloric acid, hydrobromic acid, or sulfuric acid, more preferably hydrochloric acid or hydrobromic acid, and most preferably hydrochloric acid. .
- the salt of compound (5) can be converted to compound (5) by treating with a base to remove the acid.
- the base used can be, for example, an alkali metal carbonate, an alkali metal hydroxide, or an alkaline earth metal hydroxide shown in Step A-4, preferably an alkali metal hydroxide. And most preferably sodium hydroxide or potassium hydroxide.
- Step A-3 is a step for producing compound (7) by reacting compound (5) with compound (6).
- the compound (6) used is preferably methyl magnesium chloride or methyl magnesium bromide, and most preferably methyl magnesium chloride.
- the solvent used is preferably aliphatic hydrocarbons, aromatic hydrocarbons, ethers or mixtures thereof, more preferably toluene, cyclopentyl methyl ether, tetrahydrofuran, or these A mixture, most preferably a mixture of toluene and tetrahydrofuran.
- the reaction temperature is preferably ⁇ 40 to 100 ° C., and more preferably ⁇ 20 to 20 ° C.
- Step A-4 is a step for producing compound (9) by reacting compound (7) with compound (8) in the presence of a base.
- the base used is not limited as long as it can be used for the alkylation reaction of a nitrogen atom.
- alkali metal carbonates such as lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate
- Alkali metal hydrogen carbonates such as sodium hydrogen and potassium hydrogen carbonate
- Alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide
- Alkaline earth metal water such as calcium hydroxide and barium hydroxide Oxides
- alkali metal hydrides such as lithium hydride, sodium hydride, potassium hydride
- alkali metal amides such as lithium amide, sodium amide, potassium amide
- Alkali metal alkoxides such as sid
- lithium alkylamides such as lithium diisopropylamide
- lithium silylamides such as lithium bistri
- the solvent used is preferably aromatic hydrocarbons, ethers, ketones, amides, or a mixture thereof, more preferably toluene, acetone, dimethylformamide, dimethylacetamide, or A mixture of these, most preferably a mixture of toluene and dimethylformamide.
- the reaction temperature is preferably ⁇ 20 to 100 ° C., and more preferably 0 to 80 ° C.
- Step A-5 is a step of reacting compound (9) with an inorganic azide salt in the presence of a cyclic amine salt.
- the cyclic amine salt used indicates a salt formed from a cyclic amine and an acid.
- the cyclic amine forming the cyclic amine salt contains one or more nitrogen atoms in the ring, and may contain one or more atoms selected from the group consisting of oxygen and sulfur atoms.
- nitrogen atoms in the ring
- the cyclic amine is preferably N-methylpyrrolidine, N-methylpiperidine, N, N-dimethylpiperazine, N-methylthiomorpholine, N-methylhomopiperidine, or N, N- Dimethylhomopiperazine, more preferably N-methylpiperidine, N, N-dimethylpiperazine or N-methylthiomorpholine, most preferably N-methylpiperidine or N, N-dimethylpiperazine .
- the acid that forms the cyclic amine salt is not particularly limited as long as it can form a salt with an amine.
- organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, pentafluoropropionic acid, and oxalic acid
- Organic sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, trifluoromethanesulfonic acid
- hydrogen chloride hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid
- Inorganic acids such as nitric acid, boric acid, carbonic acid, hydrogen sulfide, hydrogen azide, preferably organic acids or inorganic acids, and more preferably acetic acid, trifluoroacetic acid, hydrochloric acid, bromide Hydrogen acid, sulfuric acid, or hydrogen azide, more preferably hydro
- the cyclic amine salt is preferably N-methylpyrrolidine, N-methylpiperidine, N, N-dimethylpiperazine, N-methylmorpholine, N-methylthiomorpholine, N-methylhomopiperidine, or N, N-dimethylhomo Piperazine hydrochloride or hydrobromide, more preferably N-methylpiperidine, N, N-dimethylpiperazine, N-methylmorpholine, or N-methylthiomorpholine hydrochloride or hydrobromide N-methylpiperidine, N, N-dimethylpiperazine, or hydrochloride or hydrobromide of N-methylmorpholine, and even more preferably N-methylpiperidine hydrochloride N, N-dimethylpiperazine dihydrochloride or N-methylmorpholine hydrochloride, most preferably - methylpiperidine hydrochloride or N, N- dimethylpiperazine dihydrochloride.
- hydrochloride includes monohydrochloride and dihydrochloride
- hydrobromide includes monohydrobromide and dihydrobromide
- step A-5 a commercially available cyclic amine salt can be used, and a cyclic amine salt can also be formed from a cyclic amine and an acid in the reaction solution.
- the relative amount (molar ratio) of the cyclic amine salt to the compound (9) is preferably 1 to 5, more preferably 2 to 4, and further preferably 2.5 to 3. .5.
- the inorganic azide salt used is preferably sodium azide.
- the solvent used is preferably an aromatic hydrocarbon, an ether, a ketone, an amide, or a mixture thereof, more preferably an aromatic hydrocarbon, and even more preferably.
- Toluene or xylene most preferably toluene.
- the solvent used is preferably toluene, xylene, cyclopentyl methyl ether, methyl isobutyl ketone, dimethylformamide, or a mixture thereof.
- the reaction temperature is preferably 0 to 200 ° C., and more preferably 80 to 150 ° C.
- the reaction time is preferably 1 hour to 72 hours, and more preferably 3 to 48 hours.
- the excess inorganic azide salt can be decomposed with nitrite (preferably sodium nitrite or potassium nitrite) under acidic conditions.
- nitrite preferably sodium nitrite or potassium nitrite
- Step A-6 is a step for producing compound (10) by hydrolyzing the compound obtained in step A-5 under basic conditions.
- the base used is not particularly limited as long as it can be used for hydrolysis of ester groups.
- the alkali metal carbonate, alkali metal hydroxide, or alkaline earth metal shown in the step A-4 is used. It is a hydroxide, preferably an alkali metal hydroxide, and most preferably sodium hydroxide or potassium hydroxide.
- the solvent used is preferably an aromatic hydrocarbon, alcohol, or a mixture thereof, more preferably toluene, xylene, methanol, ethanol, 2-propanol, or a mixture thereof. And most preferred is a mixture of toluene and 2-propanol.
- a common solvent is preferably used.
- water necessary for hydrolysis is used.
- the reaction temperature is preferably 0 to 200 ° C., and more preferably 0 to 40 ° C.
- the reaction time is preferably 1 hour to 72 hours, and more preferably 1 to 10 hours.
- Step A-7 is a step for producing compound (12) by reacting compound (10) with triphenylmethyl chloride and then reacting the obtained compound with compound (11).
- Step A-7 can be performed according to a known method or a method analogous thereto [for example, Examples 79 (a) and 78 (B) of JP-B-7-121918 (corresponding to US Pat. No. 5,616,599). a)].
- Step A-8 is a step for producing compound (13) by removing the triphenylmethyl group of compound (12) in the presence of an acid.
- Step A-8 can be carried out according to a known method or a method analogous thereto [for example, Example 78 (b) of JP-B-7-121918 (corresponding US Pat. No. 5,616,599)].
- Method B is a method for producing compound (9) used in Method A.
- Step B-1 is a step of producing compound (14) by reacting compound (5) with compound (8) in the presence of a base.
- Step B-1 can be performed according to the same method as Step A-4.
- Step B-2 is a step of producing compound (9) by reacting compound (14) with compound (6).
- the step B-2 can be performed according to the same method as the step A-3.
- the production method of the present invention is superior to known production methods from an industrial viewpoint such as industrial practicality, total yield, reaction selectivity, and provision of a high-purity target compound (particularly in the following points).
- both groups may react with the nucleophile, and it is predicted that the target compound cannot be obtained in good yield.
- a cyano group of a compound having a cyano group and an ester group reacts selectively (for example, Chemistry Letters, 1983, Volume 8, p.1231; Tetrahedron Letter, 2000, 41 Vol., P.8803; Journal of Organometallic Chemistry, 1991, 403Vol.403, p.21).
- Example 1 Diethyl Dioxobutanedioate (Step A-1) Example 1 was performed under light-shielding conditions.
- Example 2 Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate (Step A-2) Example 2 was performed under light shielding conditions.
- Example 3 Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate (Steps A-1 and A-2) Example 3 was performed under light shielding conditions.
- Example 4 Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate (Steps A-1 and A-2) Example 4 was performed under light shielding conditions.
- Example 5 Diethyl 1H-imidazole-4,5-dicarboxylate (Steps A-1 and A-2) Example 5 was performed under light shielding conditions.
- Example 6 Ethyl 4- (1-hydroxy-1-methylethyl) -2-propyl-1H-imidazole-5-carboxylate (Step A-3) Under a nitrogen atmosphere, diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate (9.7 g) obtained in Example 2 was dissolved in toluene (9 ml) and tetrahydrofuran (18 ml). A mixture of methylmagnesium chloride in tetrahydrofuran (3M, 52.4 ml) and toluene (20 ml) was added dropwise over 5 hours under ice cooling. The reaction solution is stirred for 1.5 hours and then added to water.
- Example 7 Ethyl 1- (2′-cyanobiphenyl-4-yl) methyl-4- (1-hydroxy-1-methylethyl) -2-propyl-1H-imidazole-5-carboxylate (A-4 Process) Under a nitrogen atmosphere, ethyl 4- (1-hydroxy-1-methylethyl) -2-propyl-1H-imidazole-5-carboxylate (8.09 g) obtained in Example 6 was added to toluene (28.3 ml) and Dissolved in N, N-dimethylacetamide (18 ml), sodium ethoxide (2.43 g) was added to the reaction solution.
- Example 8 4- (1-Hydroxy-1-methylethyl) -2-propyl-1- [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl-1H-imidazole-5 -Carboxylic acid (Steps A-5 and A-6)
- Example 8a Ethyl 1- (2′-cyanobiphenyl-4-yl) methyl-4- (1-hydroxy-1-methylethyl) -2-propyl-1H-imidazole-5-carboxylate obtained in Example 7 (2 0.0 g) in toluene (3 ml) was added sodium azide (0.9 g) and N, N′-dimethylpiperazine dihydrochloride (1.3 g) and the reaction was stirred at 96-100 ° C.
- reaction solution was cooled to 40 ° C. or lower, and toluene and 2-propanol were added.
- the reaction solution was added to a 14.6 wt% sodium nitrite aqueous solution, and 20 wt% hydrochloric acid was added to the reaction mixture to adjust the pH of the reaction mixture to 3.8.
- Toluene was added to the reaction mixture, the organic layer was separated, and washed with 10 wt% brine.
- a 5 wt% aqueous sodium hydroxide solution was added to the organic layer, and the reaction mixture was stirred for 2 hours under ice cooling.
- Example 8a can also be performed using the following solvent instead of toluene.
- the solvents used and the reaction yield are shown in Table 1.
- Table 1 _______________________________________
- Example Solvent Yield (%) ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ 8a
- Xylene 90 8c Cyclopentyl methyl ether 91 8d methyl isobutyl ketone 90 8e Toluene / N, N-dimethylformamide [9/1 (v / v)] 91 ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- Step B-1 Diethyl 1- (2′-cyanobiphenyl-4-yl) methyl-2-propyl-1H-imidazole-4,5-dicarboxylate (Step B-1) Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate (30.7 g) and 4 ′-(bromomethyl) biphenyl-2-carbonitrile (33.4 g) obtained in Example 2 were added to acetone (45 ml). ) And N, N-dimethylacetamide (45 ml), potassium carbonate (29.3 g) was added to the reaction solution, and the reaction solution was stirred at 55 ° C. for 2 hours.
- Example 10 Ethyl 1- (2′-cyanobiphenyl-4-yl) methyl-4- (1-hydroxy-1-methylethyl) -2-propyl-1H-imidazole-5-carboxylate (B-2) Process) Under a nitrogen atmosphere and ice cooling, toluene (38.5 ml), methylmagnesium chloride in tetrahydrofuran (3.0 M, 9.05 ml) and diethyl 1- (2′-cyanobiphenyl obtained in Example 9) were used. A toluene solution (16.5 ml) of -4-yl) methyl-2-propyl-1H-imidazole-4,5-dicarboxylate (5.5 g) was added dropwise simultaneously over 3 hours.
- the reaction solution was stirred for 30 minutes and then added to water, and 2N hydrochloric acid was added to the reaction mixture to adjust the pH of the reaction mixture to 2.2.
- the organic layer was washed with water and concentrated under reduced pressure to about half volume, then Isopar E was added, and the mixture was stirred at room temperature for 16 hours, and further stirred under ice cooling for 1 hour.
- the precipitated crystals were collected by filtration and dried under reduced pressure to give the title compound (4.9 g) as white crystals.
- the various spectral data of the obtained compound were in agreement with those of the compound of Example 7.
- Example 11 Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate (Steps A-1 and A-2)
- Example 11a Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate hydrochloride hydrochloride Example 11a was performed under light-shielding conditions.
- L-tartaric acid diethyl ester (50.0 g), acetic acid (900 ml), 1,3-dibromo-5,5-dimethylhydantoin (149.1 g), and 2,2′-azobis (4-methoxy-2,4 -Dimethylvaleronitrile) (750 mg) was mixed, and the reaction solution was stirred at 70 ° C. for 2 hours and then at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to about 300 ml to obtain an acetic acid solution of diethyl dioxobutanedioate as a yellow liquid.
- Example 11b Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate hydrochloride obtained in Example 11a (50. 0 g) and sodium chloride (50.0 g) were dissolved in water (500 ml), 5N aqueous sodium hydroxide solution (30 ml) was added to the solution, and the mixture was stirred for 1 hour under ice-cooling. The precipitated crystals were collected by filtration and dried under reduced pressure to give the title compound (40.7 g) as white crystals. Various spectral data of the obtained compound were in agreement with those of the compound of Example 2.
- Reference Example 1 Diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate Reference Example 1 was performed under light-shielding conditions.
- 1,3-Dibromo-5,5-dimethylhydantoin (6.0 g) was added to an acetic acid solution (20 ml) of L-tartaric acid diethyl ester (2.0 g), and the reaction solution was stirred at 55 ° C. for 3 hours.
- the reaction solution was concentrated under reduced pressure to 10 ml.
- a tetrahydrofuran suspension (20 ml) of ammonium acetate (6.0 g) the acetic acid solution (10 ml) obtained above and a tetrahydrofuran solution (12 ml) of butanal (1.04 g) were added dropwise, and the reaction solution was dissolved. Stir at 60 ° C. for 3 hours.
- 1,3-Dibromo-5,5-dimethylhydantoin (3.3 g) was added to an ethyl acetate solution (34.2 ml) of L-tartaric acid diethyl ester (2.0 g), and the reaction solution was stirred at room temperature for 3 hours. .
- Acetic acid (17 ml) was added to the reaction solution, and then 36% formaldehyde aqueous solution (3.45 ml) was added at an internal temperature of 10 ° C. or lower under ice cooling, followed by ammonium acetate (17.2 g) at an internal temperature of 10 ° C. Added below.
- the reaction was stirred at room temperature for 30 minutes and at 50 ° C. for 3 hours.
- 1,3-Dibromo-5,5-dimethylhydantoin (3.3 g) was added to an ethyl acetate solution (34.2 ml) of L-tartaric acid diethyl ester (2.0 g), and the reaction solution was stirred at room temperature for 3 hours. .
- Acetic acid (17 ml) was added to the reaction solution, and then 36% formaldehyde aqueous solution (3.45 ml) was added at an internal temperature of 10 ° C. or lower under ice cooling, followed by ammonium acetate (17.2 g) at an internal temperature of 10 ° C. Added below.
- the reaction was stirred at room temperature for 30 minutes and at 50 ° C. for 3 hours.
- the production method of the present invention is superior to known production methods from an industrial viewpoint such as industrial practicality, total yield, reaction selectivity, and provision of a high-purity target compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
[1] 式(1)
次いで、得られた化合物をアンモニア生成試薬、および、式R1CHO[式中、R1は、水素原子またはC1-C4アルキル基を示す。]を有する化合物または式R1C(ORb)3[式中、R1は、水素原子またはC1-C4アルキル基を示し、Rbは、C1-C6アルキル基を示す。]を有する化合物と反応させることによる、
式(5)
[2] R1が、1-プロピル基であり、式R1CHOを有する化合物が使用される、[1]に記載された製造方法。
[3] Raが、エチル基である[1]または[2]に記載された製造方法。
[4] ラジカル開始試薬が、アゾビス化合物である[1]乃至[3]のいずれかに記載された製造方法。
[5] ラジカル開始試薬が、2,2’-アゾビス(4-メトキシ-2,4-ジメチルバレロニトリル)である[1]乃至[3]のいずれかに記載された製造方法。
[6] 酸化剤が、ハロゲノスクシンイミド化合物またはジハロゲノヒダントイン化合物である[1]乃至[5]のいずれかに記載された製造方法。
[7] 酸化剤が、1,3-ジブロモー5,5-ジメチルヒダントインである[1]乃至[5]のいずれかに記載された製造方法。
[8] アンモニア生成試薬が、アンモニウム塩である[1]乃至[7]のいずれかに記載された製造方法。
[9] アンモニア生成試薬が、酢酸アンモニウムである[1]乃至[7]のいずれかに記載された製造方法。
[10] 反応が遮光条件下で行われる[1]乃至[9]のいずれかに記載された製造方法。
[11] R1が、1-プロピル基であり、Raが、エチル基であり、ラジカル開始試薬が、アゾビス化合物であり、酸化剤が、ハロゲノスクシンイミド化合物またはジハロゲノヒダントイン化合物であり、アンモニア生成試薬が、アンモニウム塩であり、式R1CHOを有する化合物が使用される、[1]に記載された製造方法。
[12] R1が、1-プロピル基であり、Raが、エチル基であり、ラジカル開始試薬が、2,2’-アゾビス(4-メトキシ-2,4-ジメチルバレロニトリル)であり、酸化剤が、1,3-ジブロモー5,5-ジメチルヒダントインであり、アンモニア生成試薬が、酢酸アンモニウムであり、式R1CHOを有する化合物が使用され、反応が遮光条件下で行われる、[1]に記載された製造方法。
[13] 式(1)
式(2)
[14] Raが、エチル基であり、ラジカル開始試薬が、アゾビス化合物であり、酸化剤が、ハロゲノスクシンイミド化合物またはジハロゲノヒダントイン化合物である、[13]に記載された製造方法。
[15] Raが、エチル基であり、ラジカル開始試薬が、2,2’-アゾビス(4-メトキシ-2,4-ジメチルバレロニトリル)であり、酸化剤が、1,3-ジブロモー5,5-ジメチルヒダントインであり、反応が遮光条件下で行われる、[13]に記載された製造方法。
[16] 式(9b)
式M(N3)n[式中、Mは、アルカリ金属またはアルカリ土類金属を示し、nは、1または2を示す。]を有する無機アジ化塩を、環状アミン塩の存在下にて芳香族炭化水素類中において反応させ、得られた化合物を加水分解することによる、
式(10a)
[17] Raが、エチル基である[16]に記載された製造方法。
[18] 無機アジ化塩が、アジ化ナトリウムである[16]または[17]に記載された製造方法。
[19] 環状アミン塩が、N-メチルピロリジン、N-メチルピペリジン、N,N-ジメチルピペラジン、N-メチルモルホリン、N-メチルチオモルホリン、N-メチルホモピペリジン、または、N,N-ジメチルホモピペラジンの塩酸塩もしくは臭化水素酸塩である[16]乃至[18]のいずれかに記載された製造方法。
[20] 環状アミン塩が、N-メチルピペリジン、N,N-ジメチルピペラジン、N-メチルモルホリン、または、N-メチルチオモルホリンの塩酸塩もしくは臭化水素酸塩である[16]乃至[18]のいずれかに記載された製造方法。
[21] 環状アミン塩が、N-メチルピペリジン塩酸塩、N,N-ジメチルピペラジン二塩酸塩、または、N-メチルモルホリン塩酸塩である[16]乃至[18]のいずれかに記載された製造方法。
[22] Raが、エチル基であり、無機アジ化塩が、アジ化ナトリウムであり、環状アミン塩が、N-メチルピロリジン、N-メチルピペリジン、N,N-ジメチルピペラジン、N-メチルモルホリン、N-メチルチオモルホリン、N-メチルホモピペリジン、または、N,N-ジメチルホモピペラジンの塩酸塩もしくは臭化水素酸塩である、[16]に記載された製造方法。
[23] Raが、エチル基であり、無機アジ化塩が、アジ化ナトリウムであり、環状アミン塩が、N-メチルピペリジン塩酸塩、N,N-ジメチルピペラジン二塩酸塩、または、N-メチルモルホリン塩酸塩である、[16]に記載された製造方法。
[24] 式(14)
式(9)
[25] R1が、1-プロピル基であり、Raが、エチル基である[24]に記載された製造方法。
[26] Xが、クロロ基である[24]または[25]に記載された製造方法。
[27] R1が、1-プロピル基であり、Raが、エチル基であり、Xが、クロロ基である、[24]に記載された製造方法。
[28] [1]乃至[12]のいずれかに記載された製造方法を反応工程の一部に含む、式(13a)
[29] [13]乃至[15]のいずれかに記載された製造方法を反応工程の一部に含む、式(13a)
[30] [16]乃至[23]のいずれかに記載された製造方法を反応工程の一部に含む、式(13a)
[31] [24]乃至[27]のいずれかに記載された製造方法を反応工程の一部に含む、式(13a)
[32] 式(13a)
[33] Raが、エチル基である[32]に記載された式(14a)を有する化合物。
本発明において、各置換基は、以下に示された意味を有する。
本発明の製造方法は、下記A法またはB法にしたがって行うことができる。
(A法)
A法[A法(1)およびA法(2)]は、化合物(13)の製造方法を示す。
(A-1工程)
A-1工程は、公知の化合物(1)をラジカル開始試薬および酸の存在下にて、酸化剤を用いて酸化することにより、化合物(2)を製造する工程である。A-1工程において、化合物(1)の代わりに、その光学異性体またはラセミ体を使用することができる。
(A-2工程)
A-2工程は、化合物(2)をアンモニア生成試薬、および、化合物(3)または化合物(4)と反応させることにより、化合物(5)を製造する工程である。
(A-3工程)
A-3工程は、化合物(5)を化合物(6)と反応させることにより、化合物(7)を製造する工程である。
(A-4工程)
A-4工程は、化合物(7)を塩基の存在下にて化合物(8)と反応させることにより、化合物(9)を製造する工程である。
(A-5工程)
A-5工程は、化合物(9)を環状アミン塩の存在下にて無機アジ化塩と反応させる工程である。
(A-6工程)
A-6工程は、A-5工程で得られた化合物を塩基性条件下にて加水分解することにより、化合物(10)を製造する工程である。
(A-7工程)
A-7工程は、化合物(10)をトリフェニルメチルクロリドと反応させ、次いで得られた化合物を化合物(11)と反応させることにより、化合物(12)を製造する工程である。
(A-8工程)
A-8工程は、化合物(12)のトリフェニルメチル基を酸の存在下にて除去することにより、化合物(13)を製造する工程である。
(B法)
B法は、A法において使用される化合物(9)を製造する方法である。
(B-1工程)
B-1工程は、化合物(5)を塩基の存在下にて化合物(8)と反応させることにより、化合物(14)を製造する工程である。
(B-2工程)
B-2工程は、化合物(14)を化合物(6)と反応させることにより、化合物(9)を製造する工程である。
(実施例1)ジエチル ジオクソブタンジオエート (A-1工程)
実施例1は、遮光条件下で行われた。
1H-NMR(400MHz,D2O)δ:1.31(t,J=7.0Hz,6H),4.29(q,J=7.0Hz,4H)。
(実施例2)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート (A-2工程)
実施例2は、遮光条件下で行われた。
1H-NMR(400MHz,CDCl3)δ:0.97(t,J=7.4Hz,3H),1.38(t,J=7.2Hz,6H),1.79(dt,J=7.4,7.7Hz,2H),2.76(t,J=7.7Hz,2H),4.39(q,J=7.2Hz,4H),10.5(brs,1H)。
元素分析:Calc.C;56.68%、H;7.13%、N;11.02%
Obsd.C;56.82%、H;7.23%、N;11.04%。
(実施例3)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート (A-1およびA-2工程)
実施例3は、遮光条件下で行われた。
(実施例4)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート (A-1およびA-2工程)
実施例4は、遮光条件下で行われた。
(実施例5)ジエチル 1H-イミダゾール-4,5-ジカルボキシレート (A-1およびA-2工程)
実施例5は、遮光条件下で行われた。
HPLC分析条件:
カラム:SHISEIDO CAPCELL PAK CN UG120 250×4.6mm
移動相:20mMリン酸緩衝液(pH7)/アセトニトリル=70/30
流速:1.0ml/min
検出波長:254nm
カラム温度40℃
保持時間:4.5min。
1H-NMR(400MHz,DMSO-d6)δ:1.26(t,J=7.0Hz,6H),4.28(q,J=7.0Hz,4H),7.90(s,1H),13.53(brs,1H)。
(実施例6)エチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1H-イミダゾール-5-カルボキシレート (A-3工程)
窒素雰囲気下、実施例2で得られたジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート(9.7g)をトルエン(9ml)およびテトラヒドロフラン(18ml)に溶解し、その反応液に氷冷下、メチルマグネシウムクロリドのテトラヒドロフラン溶液(3M,52.4ml)およびトルエン(20ml)の混合液を5時間かけて滴下した。反応液を1.5時間攪拌した後に水へ添加し、反応混合物に3規定塩酸を加えて反応混合物のpHを7に調整し、有機層を10重量%食塩水にて洗浄後、水層をトルエンにて抽出した。有機層を合わせ、溶媒を減圧留去し、標題化合物(8.09g)を褐色油状物として得た。
1H-NMR(400MHz,CDCl3)δ:0.94(t,J=7.4Hz,3H),1.31(t,J=7.2Hz,6H),1.62(s,6H),1.72(dt,J=7.4,7.8Hz,2H),2.66(t,J=7.8Hz,2H),4.34(q,J=7.2Hz,2H),6.04(brs,1H)。
(実施例7)エチル 1-(2’-シアノビフェニル-4-イル)メチル-4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1H-イミダゾール-5-カルボキシレート (A-4工程)
窒素雰囲気下、実施例6で得られたエチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1H-イミダゾール-5-カルボキシレート(8.09g)をトルエン(28.3ml)およびN,N-ジメチルアセトアミド(18ml)に溶解し、その反応液にナトリウムエトキシド(2.43g)を加えた。反応液を室温にて1時間攪拌した後に、4’-(ブロモメチル)ビフェニル-2-カルボニトリル(9.70g)を加え、反応液を40℃にて4時間攪拌した。反応液を室温まで冷却した後、5.4重量%食塩水に添加して、水層をトルエンにて抽出した。有機層を合わせ、約半分の容量まで減圧濃縮した後、アイソパーEを加え、室温にて16時間攪拌し、さらに氷冷下、1時間攪拌した。析出した結晶を濾取後、減圧乾燥し、標題化合物(13.1g)を白色結晶として得た。
1H-NMR(400MHz,CDCl3)δ:0.97(t,J=7.4Hz,3H),1.16(t,J=7.2Hz,3H),1.65(s,6H),1.74(dt,J=7.4,7.8Hz,2H),2.66(t,J=7.8Hz,2H),4.23(q,J=7.2Hz,2H),5.52(s,1H),5.81(s,1H),7.05(d,J=8.8Hz,2H),7.42-7.54(m,4H),7.65(dt,J=1.6,7.8Hz,1H),7.77(dd,J=1.2,8.0Hz,1H)。
元素分析:Calc.C;72.37%、H;6.77%、N;9.74%
Obsd.C;72.41%、H;6.81%、N;9.69%。
(実施例8)4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル-1H-イミダゾール-5-カルボン酸 (A-5およびA-6工程)
(実施例8a)
実施例7で得られたエチル 1-(2’-シアノビフェニル-4-イル)メチル-4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1H-イミダゾール-5-カルボキシレート(2.0g)のトルエン溶液(3ml)にアジ化ナトリウム(0.9g)およびN,N’-ジメチルピペラジン二塩酸塩(1.3g)を加え、反応液を96から100℃にて24時間攪拌した。反応液を40℃以下に冷却し、トルエンおよび2-プロパノールを加えた。反応液を14.6重量%亜硝酸ナトリウム水溶液へ添加し、反応混合物に20重量%塩酸を加えて反応混合物のpHを3.8に調整した。反応混合物にトルエンを加えて有機層を分離し、10重量%食塩水にて洗浄した。有機層に5重量%水酸化ナトリウム水溶液を加え、反応混合物を氷冷下、2時間攪拌した。分離した水層にアセトニトリルを加えた後、20重量%塩酸を加えて反応混合物のpHを3.8に調整した。析出した結晶を濾取して乾燥し、標題化合物(1.94g)を白色結晶として得た。
1H-NMR(400MHz,DMSO-d6)δ:0.85(t,J=7.3Hz,3H),1.53(tq,J=7.3,7.6Hz,2H),1.53(s,6H),2.57(t,J=7.6Hz,2H),5.64(s,2H),6.94(d,J=8.3Hz,2H),7.06(d,J=8.3Hz,2H),7.51-7.59(m,2H),7.62-7.70(m,2H)。
[表1]
_________________________________
実施例 溶媒 収率(%)
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
8a トルエン 89
8b キシレン 90
8c シクロペンチルメチルエーテル 91
8d メチルイソブチルケトン 90
8e トルエン/N,N-ジメチルホルムアミド[9/1(v/v)] 91
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
実施例8aは、N,N’-ジメチルピペラジン二塩酸塩の代わりに下記の環状アミン塩を用いて行うこともできる。使用される環状アミン塩のエチル 1-(2’-シアノビフェニル-4-イル)メチル-4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1H-イミダゾール-5-カルボキシレートに対するモル比は、3である。使用された環状アミン塩および反応収率を表2に示す。比較として、非環状アミン塩であるトリエチルアミン塩酸塩を用いた場合の反応収率(特許第3521304号公報の実施例2)を合わせて示す。
[表2]
______________________________
実施例 環状アミン塩 収率(%)
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
8a N,N’-ジメチルピペラジン二塩酸塩 89
8f N-メチルピペリジン塩酸塩 89
8g N-メチルモルホリン塩酸塩 90
8h N-メチルピロリジン塩酸塩 87
------------------------------
トリエチルアミン塩酸塩 72
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
表2の結果より、本発明の製造方法[化合物(9)から化合物(10)を製造する方法]は、公知のY法に示された反応よりも収率の点で優れることが示された。
(実施例9)ジエチル 1-(2’-シアノビフェニル-4-イル)メチル-2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート (B-1工程)
実施例2で得られたジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート(30.7g)および4’-(ブロモメチル)ビフェニル-2-カルボニトリル(33.4g)をアセトン(45ml)およびN,N-ジメチルアセトアミド(45ml)に溶解して、その反応液に炭酸カリウム(29.3g)を加え、反応液を55℃で2時間攪拌した。反応液を室温まで冷却した後、水およびトルエンを加え、有機層を水にて洗浄した。溶媒を減圧留去し、標題化合物(53.8g)を黄色結晶として得た。
1H-NMR(400MHz,CDCl3)δ:0.96(t,J=7.4Hz,3H),1.25(t,J=7.2Hz,3H),1.39(t,J=7.0Hz,3H),1.75(dt,J=7.4,7.8Hz,2H),2.69(t,J=7.8Hz,2H),4.27(q,J=7.2Hz,2H),4.40(q,J=7.0Hz,2H),5.48(s,2H),7.13(d,J=8.4Hz,2H),7.42-7.54(m,4H),7.65(dt,J=1.2,7.6Hz,1H),7.76(dd,J=1.2,7.6Hz,1H)。
元素分析:Calc.C;70.09%、H;6.11%、N;9.43%
Obsd.C;70.28%、H;6.13%、N;9.48%。
(実施例10)エチル 1-(2’-シアノビフェニル-4-イル)メチル-4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1H-イミダゾール-5-カルボキシレート (B-2工程)
窒素雰囲気下および氷冷下、トルエン(38.5ml)に、メチルマグネシウムクロリドのテトラヒドロフラン溶液(3.0M,9.05ml)、および、実施例9で得られたジエチル 1-(2’-シアノビフェニル-4-イル)メチル-2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート(5.5g)のトルエン溶液(16.5ml)を3時間かけて同時に滴下した。反応液を30分間攪拌した後、水に添加し、反応混合物に2規定塩酸を加えて反応混合物のpHを2.2に調整した。有機層を水にて洗浄して、約半分の容量まで減圧濃縮した後、アイソパーEを加え、室温にて16時間攪拌し、さらに氷冷下、1時間攪拌した。析出した結晶を濾取後、減圧乾燥し、標題化合物(4.9g)を白色結晶として得た。得られた化合物の各種スペクトルデータは、実施例7の化合物のものと一致した。
(実施例11)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート (A-1およびA-2工程)
(実施例11a)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート・塩酸塩
実施例11aは、遮光条件下で行われた。
1H-NMR(400MHz,CD3OD)δ:1.03(t,J=7.3Hz,3H),1.42(t,J=7.3Hz,6H),1.84(dt,J=7.3,7.6Hz,2H),2.98(t,J=7.6Hz,2H),4.47(q,J=7.3Hz,4H),4.97(brs,2H)。
元素分析:Calc.C;49.57%、H;6.59%、N;9.64%
Obsd.C;49.35%、H;6.53%、N;9.73%。
(実施例11b)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート
実施例11aで得られたジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート・塩酸塩(50.0g)および食塩(50.0g)を水(500ml)へ溶解し、この溶液に5規定水酸化ナトリウム水溶液(30ml)を加えた後、氷冷下、1時間攪拌した。析出した結晶を濾取後、減圧乾燥し、標題化合物(40.7g)を白色結晶として得た。得られた化合物の各種スペクトルデータは、実施例2の化合物のものと一致した。
(参考例1)ジエチル 2-プロピル-1H-イミダゾール-4,5-ジカルボキシレート
参考例1は、遮光条件下で行われた。
HPLC分析条件:
カラム:SHISEIDO CAPCELL PAK CN UG120 250×4.6mm
移動相:20mM酢酸アンモニウム水溶液/アセトニトリル=65/35
流速:1.0ml/min
検出波長:210nm
カラム温度40℃
保持時間:5.8min。
(参考例2)ジエチル 1H-イミダゾール-4,5-ジカルボキシレート
参考例2は、遮光条件下で行われた。
(参考例3)ジエチル 1H-イミダゾール-4,5-ジカルボキシレート
参考例3は、遮光されない条件下で行われた。
(参考例4)エチル 4-(1-ヒドロキシ-1-メチルエチル)-2-プロピル-1-[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル-1H-イミダゾール-5-カルボキシレート
窒素雰囲気下および氷冷下、メチルマグネシウムクロリドのテトラヒドロフラン溶液(3.0M,1.4ml)に、ジエチル 2-プロピル-1-[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル-1H-イミダゾール-4,5-ジカルボキシレート(0.5g)のテトラヒドロフラン溶液(5.0ml)を2時間かけて滴下した。反応液を室温にて3時間攪拌した後、1規定塩酸を加え、水層を酢酸エチルにて抽出した。有機層を合わせて、硫酸マグネシウムにて乾燥した。得られた酢酸エチル溶液をHPLCにて定量分析した結果、標題化合物(420.1mg、収率:85%)が得られたことが示された。
HPLC分析条件:
カラム:WATERS XTERRA RP18 150×4.6mm
移動相:20mMリン酸緩衝液(pH3)/アセトニトリル=60/40
流速:1.0ml/min
検出波長:254nm
カラム温度40℃
保持時間:4.9min。
1H-NMR(400MHz,CDCl3)δ:0.90(t,J=7.2Hz,3H),1.11(t,J=7.0Hz,3H),1.44(s,6H),1.66(m,2H),2.37(t,J=7.2Hz,2H),4.17(q,J=7.1Hz,2H),5.38(s,2H),6.76(d,J=7.6Hz,2H),7.08(d,J=7.6Hz,2H),7.41(t,J=7.6Hz,4H),7.51(t,J=7.2Hz,1H),7.58(t,J=7.4Hz,1H),7.82(d,J=6.8Hz,1H)。
(参考例5)
トルエンの代わりに下記の溶媒を用いて、実施例8aと同様の方法にしたがって反応を行った。使用された溶媒および反応収率を表3に示す。
[表3]
__________________________________
参考例 溶媒 収率(%)
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
5a N,N-ジメチルホルムアミド 73
5b N,N-ジメチルアセトアミド 39
5c 1,3-ジメチル-2-イミダゾリジノン 51
 ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄ ̄
Claims (33)
- R1が、1-プロピル基であり、式R1CHOを有する化合物が使用される、請求項1に記載された製造方法。
- Raが、エチル基である請求項1または2に記載された製造方法。
- ラジカル開始試薬が、アゾビス化合物である請求項1乃至3のいずれかに記載された製造方法。
- ラジカル開始試薬が、2,2’-アゾビス(4-メトキシ-2,4-ジメチルバレロニトリル)である請求項1乃至3のいずれかに記載された製造方法。
- 酸化剤が、ハロゲノスクシンイミド化合物またはジハロゲノヒダントイン化合物である請求項1乃至5のいずれかに記載された製造方法。
- 酸化剤が、1,3-ジブロモー5,5-ジメチルヒダントインである請求項1乃至5のいずれかに記載された製造方法。
- アンモニア生成試薬が、アンモニウム塩である請求項1乃至7のいずれかに記載された製造方法。
- アンモニア生成試薬が、酢酸アンモニウムである請求項1乃至7のいずれかに記載された製造方法。
- 反応が遮光条件下で行われる請求項1乃至9のいずれかに記載された製造方法。
- R1が、1-プロピル基であり、Raが、エチル基であり、ラジカル開始試薬が、アゾビス化合物であり、酸化剤が、ハロゲノスクシンイミド化合物またはジハロゲノヒダントイン化合物であり、アンモニア生成試薬が、アンモニウム塩であり、式R1CHOを有する化合物が使用される、請求項1に記載された製造方法。
- R1が、1-プロピル基であり、Raが、エチル基であり、ラジカル開始試薬が、2,2’-アゾビス(4-メトキシ-2,4-ジメチルバレロニトリル)であり、酸化剤が、1,3-ジブロモー5,5-ジメチルヒダントインであり、アンモニア生成試薬が、酢酸アンモニウムであり、式R1CHOを有する化合物が使用され、反応が遮光条件下で行われる、請求項1に記載された製造方法。
- Raが、エチル基であり、ラジカル開始試薬が、アゾビス化合物であり、酸化剤が、ハロゲノスクシンイミド化合物またはジハロゲノヒダントイン化合物である、請求項13に記載された製造方法。
- Raが、エチル基であり、ラジカル開始試薬が、2,2’-アゾビス(4-メトキシ-2,4-ジメチルバレロニトリル)であり、酸化剤が、1,3-ジブロモー5,5-ジメチルヒダントインであり、反応が遮光条件下で行われる、請求項13に記載された製造方法。
- Raが、エチル基である請求項16に記載された製造方法。
- 無機アジ化塩が、アジ化ナトリウムである請求項16または17に記載された製造方法。
- 環状アミン塩が、N-メチルピロリジン、N-メチルピペリジン、N,N-ジメチルピペラジン、N-メチルモルホリン、N-メチルチオモルホリン、N-メチルホモピペリジン、または、N,N-ジメチルホモピペラジンの塩酸塩もしくは臭化水素酸塩である請求項16乃至18のいずれかに記載された製造方法。
- 環状アミン塩が、N-メチルピペリジン、N,N-ジメチルピペラジン、N-メチルモルホリン、または、N-メチルチオモルホリンの塩酸塩もしくは臭化水素酸塩である請求項16乃至18のいずれかに記載された製造方法。
- 環状アミン塩が、N-メチルピペリジン塩酸塩、N,N-ジメチルピペラジン二塩酸塩、または、N-メチルモルホリン塩酸塩である請求項16乃至18のいずれかに記載された製造方法。
- Raが、エチル基であり、無機アジ化塩が、アジ化ナトリウムであり、環状アミン塩が、N-メチルピロリジン、N-メチルピペリジン、N,N-ジメチルピペラジン、N-メチルモルホリン、N-メチルチオモルホリン、N-メチルホモピペリジン、または、N,N-ジメチルホモピペラジンの塩酸塩もしくは臭化水素酸塩である、請求項16に記載された製造方法。
- Raが、エチル基であり、無機アジ化塩が、アジ化ナトリウムであり、環状アミン塩が、N-メチルピペリジン塩酸塩、N,N-ジメチルピペラジン二塩酸塩、または、N-メチルモルホリン塩酸塩である、請求項16に記載された製造方法。
- R1が、1-プロピル基であり、Raが、エチル基である請求項24に記載された製造方法。
- Xが、クロロ基である請求項24または25に記載された製造方法。
- R1が、1-プロピル基であり、Raが、エチル基であり、Xが、クロロ基である、請求項24に記載された製造方法。
- Raが、エチル基である請求項32に記載された式(14a)を有する化合物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/996,697 US8735598B2 (en) | 2008-06-09 | 2009-06-08 | Method for producing 1-biphenylmethylimidazole compound |
ES09762446.4T ES2540062T3 (es) | 2008-06-09 | 2009-06-08 | Procedimiento de producción de un compuesto de 1-bifenilmetilimidazol |
JP2010516839A JP5415416B2 (ja) | 2008-06-09 | 2009-06-08 | 1−ビフェニルメチルイミダゾール化合物の製造方法 |
CN200980122256.7A CN102083823B (zh) | 2008-06-09 | 2009-06-08 | 1-联苯甲基咪唑化合物的制备方法 |
CA2727220A CA2727220C (en) | 2008-06-09 | 2009-06-08 | Method for producing a 1-biphenylmethylimidazole compound |
EP09762446.4A EP2298763B1 (en) | 2008-06-09 | 2009-06-08 | Method for producing 1-biphenylmethylimidazole compound |
IL209909A IL209909A (en) | 2008-06-09 | 2010-12-09 | METHOD FOR PRODUCING 1-BIPENYLMETHYLMETHYLMIDAZOLE |
HK11108788.6A HK1154577A1 (en) | 2008-06-09 | 2011-08-19 | Method for producing 1-biphenylmethylimidazole compound 1- |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-150686 | 2008-06-09 | ||
JP2008150686 | 2008-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009151016A1 true WO2009151016A1 (ja) | 2009-12-17 |
Family
ID=41416721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/060419 WO2009151016A1 (ja) | 2008-06-09 | 2009-06-08 | 1-ビフェニルメチルイミダゾール化合物の製造方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8735598B2 (ja) |
EP (1) | EP2298763B1 (ja) |
JP (1) | JP5415416B2 (ja) |
KR (1) | KR101630885B1 (ja) |
CN (1) | CN102083823B (ja) |
CA (1) | CA2727220C (ja) |
ES (1) | ES2540062T3 (ja) |
HK (1) | HK1154577A1 (ja) |
HU (1) | HUE025230T2 (ja) |
IL (1) | IL209909A (ja) |
TW (1) | TWI438194B (ja) |
WO (1) | WO2009151016A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5697593B2 (ja) | 2009-04-28 | 2015-04-08 | 第一三共株式会社 | 新規溶媒和物結晶 |
EP2426126B1 (en) | 2009-04-28 | 2014-11-19 | Daiichi Sankyo Company, Limited | Method for producing olmesartan medoxomil |
WO2013126015A1 (en) | 2012-02-23 | 2013-08-29 | N. V. Nutricia | Composition comprising non- digestible oligosaccharides |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07121918A (ja) | 1993-08-30 | 1995-05-12 | Tdk Corp | 光磁気記録媒体 |
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
JP3521304B2 (ja) | 1996-03-21 | 2004-04-19 | 東洋化成工業株式会社 | 1−(テトラゾリルビフェニルメチル)イミダゾール誘導体の製造方法 |
JP2004217542A (ja) | 2003-01-10 | 2004-08-05 | Fuji Photo Film Co Ltd | 4,5−ジアルコキシカルボニルイミダゾールの製造方法 |
JP2006111586A (ja) * | 2004-10-15 | 2006-04-27 | Nippon Petrochemicals Co Ltd | 置換芳香族化合物の酸化方法 |
WO2007047838A2 (en) | 2005-10-20 | 2007-04-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing olmesartan medoxomil |
JP7121918B2 (ja) * | 2016-12-14 | 2022-08-19 | 大日本印刷株式会社 | 蒸着マスク装置及び蒸着マスク装置の製造方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5728703B2 (ja) * | 1972-05-05 | 1982-06-18 | ||
FI112942B3 (fi) | 1991-02-21 | 2012-03-13 | Daiichi Sankyo Co Ltd | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi |
JP3671266B2 (ja) | 1996-03-21 | 2005-07-13 | 東洋化成工業株式会社 | 5−置換テトラゾール類の製造方法 |
JP2004300118A (ja) * | 2003-04-01 | 2004-10-28 | Fuji Photo Film Co Ltd | 4,5−ジ置換カルボニルイミダゾールの製造方法 |
US20070054948A1 (en) | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
CA2575177A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Purification of olmesartan medoxomil |
CN1976926A (zh) | 2004-09-02 | 2007-06-06 | 特瓦制药工业有限公司 | 奥美沙坦酯的制备 |
EP1716139A1 (en) | 2005-01-03 | 2006-11-02 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
EA014026B1 (ru) | 2005-07-29 | 2010-08-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Способ получения олмесартан медоксомила |
SI22092A (sl) | 2005-07-29 | 2007-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo olmesartan medoksomila |
CZ299902B6 (cs) | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
WO2007148344A2 (en) | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
ITMI20061848A1 (it) | 2006-09-27 | 2008-03-28 | Dipharma Spa | Procedimento per la preparazione di composti feniltetrazolici |
CA2663981C (en) | 2006-10-09 | 2014-05-27 | Cipla Limited | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil |
EP2176253B1 (en) | 2007-08-08 | 2011-10-12 | LEK Pharmaceuticals d.d. | A process for the preparation or purification of olmesartan medoxomil or olmesartan medoxomil hydrohalide salt |
EP2036904A1 (en) | 2007-08-08 | 2009-03-18 | LEK Pharmaceuticals D.D. | A process for the preparation of olmesartan medoxomil |
WO2010026255A1 (en) | 2008-09-05 | 2010-03-11 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for preparing olmesartan medoxomil intermediate |
WO2011014611A2 (en) | 2009-07-30 | 2011-02-03 | Dr. Reddy's Laboratories Ltd. | Preparation of olmesartan medoxomil |
US20130190506A1 (en) | 2010-06-28 | 2013-07-25 | Hetero Research Foundation | Process for olmesartan medoxomil |
-
2009
- 2009-06-08 ES ES09762446.4T patent/ES2540062T3/es active Active
- 2009-06-08 US US12/996,697 patent/US8735598B2/en not_active Expired - Fee Related
- 2009-06-08 CN CN200980122256.7A patent/CN102083823B/zh not_active Expired - Fee Related
- 2009-06-08 WO PCT/JP2009/060419 patent/WO2009151016A1/ja active Application Filing
- 2009-06-08 CA CA2727220A patent/CA2727220C/en not_active Expired - Fee Related
- 2009-06-08 JP JP2010516839A patent/JP5415416B2/ja not_active Expired - Fee Related
- 2009-06-08 HU HUE09762446A patent/HUE025230T2/en unknown
- 2009-06-08 KR KR1020107027468A patent/KR101630885B1/ko active IP Right Grant
- 2009-06-08 EP EP09762446.4A patent/EP2298763B1/en not_active Not-in-force
- 2009-06-09 TW TW098119169A patent/TWI438194B/zh not_active IP Right Cessation
-
2010
- 2010-12-09 IL IL209909A patent/IL209909A/en active IP Right Grant
-
2011
- 2011-08-19 HK HK11108788.6A patent/HK1154577A1/xx not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
JPH07121918A (ja) | 1993-08-30 | 1995-05-12 | Tdk Corp | 光磁気記録媒体 |
JP3521304B2 (ja) | 1996-03-21 | 2004-04-19 | 東洋化成工業株式会社 | 1−(テトラゾリルビフェニルメチル)イミダゾール誘導体の製造方法 |
JP2004217542A (ja) | 2003-01-10 | 2004-08-05 | Fuji Photo Film Co Ltd | 4,5−ジアルコキシカルボニルイミダゾールの製造方法 |
JP2006111586A (ja) * | 2004-10-15 | 2006-04-27 | Nippon Petrochemicals Co Ltd | 置換芳香族化合物の酸化方法 |
WO2007047838A2 (en) | 2005-10-20 | 2007-04-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing olmesartan medoxomil |
JP7121918B2 (ja) * | 2016-12-14 | 2022-08-19 | 大日本印刷株式会社 | 蒸着マスク装置及び蒸着マスク装置の製造方法 |
Non-Patent Citations (7)
Title |
---|
ANNUAL REPORT OF SANKYO RESEARCH LABORATORIES, vol. 55, 2003, pages 1 - 91 |
CHEMISTRY LETTERS, vol. 8, 1983, pages 1231 |
HIROYUKI KOIKE ET AL.: "Olmesartan Medoxomil, a Novel Potent Angiotensin II Blocker", ANNUAL REPORT OF SANKYO RESEARCH LABORATORIES, vol. 55, 2003, pages 1 - 91, XP008147471 * |
JOURNAL OF ORGANOMETALLIC CHEMISTRY, vol. 403, 1991, pages 21 |
See also references of EP2298763A4 |
T.W. GREENE; P.G. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC. |
TETRAHEDRON LETTER, vol. 41, 2000, pages 8803 |
Also Published As
Publication number | Publication date |
---|---|
EP2298763B1 (en) | 2015-03-25 |
US20110092713A1 (en) | 2011-04-21 |
HUE025230T2 (en) | 2016-02-29 |
TWI438194B (zh) | 2014-05-21 |
HK1154577A1 (en) | 2012-04-27 |
IL209909A0 (en) | 2011-02-28 |
JP5415416B2 (ja) | 2014-02-12 |
CA2727220C (en) | 2015-07-28 |
KR101630885B1 (ko) | 2016-06-15 |
CN102083823B (zh) | 2015-10-07 |
KR20110015428A (ko) | 2011-02-15 |
TW201002673A (en) | 2010-01-16 |
ES2540062T3 (es) | 2015-07-08 |
EP2298763A1 (en) | 2011-03-23 |
JPWO2009151016A1 (ja) | 2011-11-17 |
EP2298763A4 (en) | 2011-10-05 |
US8735598B2 (en) | 2014-05-27 |
IL209909A (en) | 2014-07-31 |
CA2727220A1 (en) | 2009-12-17 |
CN102083823A (zh) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7190438B2 (ja) | ベンゾイル蟻酸化合物及びピリダジン化合物の製造方法 | |
JP5415416B2 (ja) | 1−ビフェニルメチルイミダゾール化合物の製造方法 | |
JP6429016B2 (ja) | トリフルオロメタンスルホンアニリド化合物の製造方法 | |
KR101428580B1 (ko) | t-부틸 2-((4R,6S)-6-포밀-2,2-디메틸-1,3-디옥산-4-일)아세테이트의 제조방법 | |
TWI403504B (zh) | 2-鹵基咪唑化合物之製造方法 | |
JP5526538B2 (ja) | 3−(2−シアノ−1−プロペニル)−2,2−ジメチルシクロプロパンカルボン酸化合物の製造方法およびその中間体 | |
JP4879907B2 (ja) | フェニル2−ピリミジニルケトン類の製造方法及びその新規中間体 | |
US9212152B2 (en) | Process for the preparation of N-hydroxy-1-(1-alkyl-1H-tetrazol-5-yl)-1-phenylmethanimine derivatives | |
JP4651969B2 (ja) | エポキシトリアゾール化合物の製造方法 | |
JP6183053B2 (ja) | テトラヒドロピラニルピリミジン化合物の製造方法 | |
JP2013006781A (ja) | ピラゾール化合物の製造方法 | |
EP3976588B1 (en) | Methods for the preparation of 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylic acid | |
JP6459709B2 (ja) | 3,3−ジフルオロ−2−ヒドロキシプロピオン酸の実用的な製造方法 | |
KR101012135B1 (ko) | 발사르탄 메틸 에스테르의 제조방법 | |
JP4084501B2 (ja) | α−メルカプトカルボン酸およびその製造方法 | |
KR101566536B1 (ko) | 로수바스타틴 중간체인 (E)-t-부틸 2-(6-(2-(4-(4-플루오로페닐)-6-이소프로필-2-(N-메틸,메틸설폰아미도)피리미딘-5-일)비닐)-2,2-디메틸-1,3-디옥산-4-일)아세테이트의 제조 방법 | |
WO2017209035A1 (ja) | ビフェニルベンズイミダゾール誘導体の製造方法 | |
JP5187534B2 (ja) | N−tert−ブトキシカルボニル−4−ホルミルピペリジンの製造方法 | |
JP2006104130A (ja) | 混合酸無水物類およびその製造方法 | |
WO2006001529A9 (ja) | 5-フタランカルボニトリル化合物の製造方法及びその中間体 | |
CN102079747A (zh) | 奥美沙坦酯关键中间体及其合成方法及由该中间体合成奥美沙坦酯的方法 | |
JP2005126434A (ja) | ベンジルイミダゾール誘導体の製造方法 | |
JP2008208047A (ja) | 1,3,4−トリメチルピラゾール−5−カルボン酸エステルの製造方法ならびに製造中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980122256.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09762446 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010516839 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2541/MUMNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009762446 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107027468 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2727220 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 209909 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12996697 Country of ref document: US |